caa a22 4500 445314893 CHVBK 20180317142643.0 cr unu---uuuuu 170323e20110901xx s 000 0 eng 10.1007/s10552-011-9806-8 doi (NATIONALLICENCE)springer-10.1007/s10552-011-9806-8 Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort [Elektronische Daten] [Theodore Brasky, Johanna Lampe, Christopher Slatore, Emily White] Objective: Inflammation plays an important role in lung carcinogenesis. Epidemiologic studies have reported inverse associations of non-steroidal anti-inflammatory drug (NSAID) use and lung cancer risk. Previously, we found that ever use of glucosamine and chondroitin, which have anti-inflammatory properties, were inversely associated with lung cancer risk. After an additional year of follow-up, we further examined the association including frequency/duration of use, interaction with factors associated with inflammation, and lung cancer histology. Methods: Participants were members of the VITamins And Lifestyle cohort. Adults, aged 50-76years, who were residents of western Washington State, completed a baseline questionnaire in 2000-2002 (n=76,904). Participants were queried on their use of glucosamine and chondroitin, over the 10years prior to baseline, and categorized as nonuser, low use <4days/week or <3years, or high use ≥4days/week and ≥3years. Lung cancer cases (n=808) were ascertained through linkage to the Surveillance, Epidemiology, and End Results cancer registry. Results: High 10-year use of glucosamine [hazard ratio (HR), 0.77; 95% CI: 0.56-1.07; p trend=0.04] but not chondroitin was associated with a reduction in lung cancer risk. The association with glucosamine was limited to adenocarcinoma (HR, 0.49; 95% CI: 0.27-0.90; p trend <0.01) and was not modified by NSAID use or smoking status. Conclusions: Our results for glucosamine use are similar to the prior human studies of NSAID use and lung cancer, both in magnitude and the limitation of the association to adenocarcinoma. Unlike NSAIDs, glucosamine has no known adverse effects. Although confirmatory studies are needed, glucosamine is an attractive candidate for lung cancer chemoprevention. Springer Science+Business Media B.V., 2011 Adenocarcinoma nationallicence Chondroitin nationallicence Glucosamine nationallicence Non-small-cell lung cancer nationallicence Small-cell lung cancer nationallicence Supplement nationallicence Brasky Theodore Cancer Prevention Unit, The Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-B402, 98109-1024, Seattle, WA, USA aut Lampe Johanna Cancer Prevention Unit, The Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-B402, 98109-1024, Seattle, WA, USA aut Slatore Christopher Health Services Research and Development, Portland Veterans Affairs Medical Center, Portland, OR, USA aut White Emily Cancer Prevention Unit, The Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-B402, 98109-1024, Seattle, WA, USA aut Cancer Causes & Control Springer Netherlands 22/9(2011-09-01), 1333-1342 0957-5243 22:9<1333 2011 22 10552 https://doi.org/10.1007/s10552-011-9806-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10552-011-9806-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Brasky Theodore Cancer Prevention Unit, The Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-B402, 98109-1024, Seattle, WA, USA aut NATIONALLICENCE 700 1- Lampe Johanna Cancer Prevention Unit, The Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-B402, 98109-1024, Seattle, WA, USA aut NATIONALLICENCE 700 1- Slatore Christopher Health Services Research and Development, Portland Veterans Affairs Medical Center, Portland, OR, USA aut NATIONALLICENCE 700 1- White Emily Cancer Prevention Unit, The Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., M4-B402, 98109-1024, Seattle, WA, USA aut NATIONALLICENCE 773 0- Cancer Causes & Control Springer Netherlands 22/9(2011-09-01), 1333-1342 0957-5243 22:9<1333 2011 22 10552 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer